Skip to main content
Top
Published in: Acta Neurochirurgica 10/2017

01-10-2017 | Original Article - Brain Tumors

Clival chordoma: a single-centre outcome analysis

Authors: Max Jägersberg, Amir El Rahal, Philipp Dammann, Doron Merkler, Damien Charles Weber, Karl Schaller

Published in: Acta Neurochirurgica | Issue 10/2017

Login to get access

Abstract

Background

The treatment of clival chordomas remains challenging. Total tumour resection is often impossible without hampering adjacent anatomical structures and causing functional sequelae. On the other hand, chordomas show limited response to non-surgical treatment modalities. Up to now, no well-established interdisciplinary treatment algorithms for clival chordomas exist. In this regard, we analysed the data from all patients that underwent interdisciplinary treatment for clival chordoma in our institution over the last 10 years.

Method

Retrospective report of all patients treated at the authors’ institution from 2005 to 2015.

Results

Thirteen patients underwent 24 surgeries, of which 2 (8%) were gross total resections and 22 (92%) incomplete resections. Neurological deterioration, endocrinological disturbances and other surgical complications were observed in six (25%), three (13%) and nine (38%) cases, respectively. Three surgeries (13%) led to an improvement of the initial preoperative neurological condition. All patients were discussed on the interdisciplinary tumour board and all underwent one type of radiotherapy following initial surgery: proton beam in 11 cases (85%) and photon beam in two (15%) cases. In the course of their recurrent disease, three patients (23%) received systemic therapy (imatinib, pazopanib and nivolumab). One patient received a personalised cellular immunotherapy. One patient (8%) was lost to follow-up. Of the remaining 12 patients, four patients (33%) died in the period of analysis; all deaths were chordoma-related. The 5-year cumulative survival rate was 83% (52–97%, CI 95%), 5-year progression-free survival rate was 53% (26-79%, CI 95%). The eight patients (66%) still alive had favourable outcome (KPS, 90 ± 10.7%). SF36 analysis among the survivors revealed 43 points for the Physical Component Summary (12% above, 38% at and 50% below the general population norm) and 47 points for the Mental Component Summary (25% above, 38% at and 38% below).

Conclusions

Our patients show a low rate of gross total resection but an outcome well comparable to other published results. This emphasises the importance of interdispiplinary treatment strategies, with surgery supplying maximal safe resection and avoiding severe neurological deficit, allowing patients to undergo adjusted radiotherapy and other treatment options in a good condition.
Literature
1.
go back to reference Almefty K, Pravdenkova S, Colli BO, Al-Mefty O, Gokden M (2007) Chordoma and chondrosarcoma: similar, but quite different, skull base tumors. Cancer 110:2457–2467CrossRefPubMed Almefty K, Pravdenkova S, Colli BO, Al-Mefty O, Gokden M (2007) Chordoma and chondrosarcoma: similar, but quite different, skull base tumors. Cancer 110:2457–2467CrossRefPubMed
2.
go back to reference Austin-Seymour M, Munzenrider J, Goitein M, Verhey L, Urie M, Gentry R, Birnbaum S, Ruotolo D, McManus P, Skates S et al (1989) Fractionated proton radiation therapy of chordoma and low-grade chondrosarcoma of the base of the skull. J Neurosurg 70:13–17CrossRefPubMed Austin-Seymour M, Munzenrider J, Goitein M, Verhey L, Urie M, Gentry R, Birnbaum S, Ruotolo D, McManus P, Skates S et al (1989) Fractionated proton radiation therapy of chordoma and low-grade chondrosarcoma of the base of the skull. J Neurosurg 70:13–17CrossRefPubMed
3.
go back to reference Azzarelli A, Quagliuolo V, Cerasoli S, Zucali R, Bignami P, Mazzaferro V, Dossena G, Gennari L (1988) Chordoma: natural history and treatment results in 33 cases. J Surg Oncol 37:185–191CrossRefPubMed Azzarelli A, Quagliuolo V, Cerasoli S, Zucali R, Bignami P, Mazzaferro V, Dossena G, Gennari L (1988) Chordoma: natural history and treatment results in 33 cases. J Surg Oncol 37:185–191CrossRefPubMed
4.
go back to reference Bompas E, Le Cesne A, Tresch-Bruneel E, Lebellec L, Laurence V, Collard O, Saada-Bouzid E, Isambert N, Blay JY, Amela EY, Salas S, Chevreau C, Bertucci F, Italiano A, Clisant S, Penel N (2015) Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French sarcoma group (GSF/GETO). Ann Oncol 26:2168–2173CrossRefPubMedPubMedCentral Bompas E, Le Cesne A, Tresch-Bruneel E, Lebellec L, Laurence V, Collard O, Saada-Bouzid E, Isambert N, Blay JY, Amela EY, Salas S, Chevreau C, Bertucci F, Italiano A, Clisant S, Penel N (2015) Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French sarcoma group (GSF/GETO). Ann Oncol 26:2168–2173CrossRefPubMedPubMedCentral
5.
go back to reference Brada M, Pijls-Johannesma M, De Ruysscher D (2007) Proton therapy in clinical practice: current clinical evidence. J Clin Oncol 25:965–970CrossRefPubMed Brada M, Pijls-Johannesma M, De Ruysscher D (2007) Proton therapy in clinical practice: current clinical evidence. J Clin Oncol 25:965–970CrossRefPubMed
6.
go back to reference Di Maio S, Temkin N, Ramanathan D, Sekhar LN (2011) Current comprehensive management of cranial base chordomas: 10-year meta-analysis of observational studies. J Neurosurg 115:1094–1105CrossRefPubMed Di Maio S, Temkin N, Ramanathan D, Sekhar LN (2011) Current comprehensive management of cranial base chordomas: 10-year meta-analysis of observational studies. J Neurosurg 115:1094–1105CrossRefPubMed
7.
go back to reference Ferraresi V, Nuzzo C, Zoccali C, Marandino F, Vidiri A, Salducca N, Zeuli M, Giannarelli D, Cognetti F, Biagini R (2010) Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients. BMC Cancer 10:22CrossRefPubMedPubMedCentral Ferraresi V, Nuzzo C, Zoccali C, Marandino F, Vidiri A, Salducca N, Zeuli M, Giannarelli D, Cognetti F, Biagini R (2010) Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients. BMC Cancer 10:22CrossRefPubMedPubMedCentral
8.
go back to reference Fraser JF, Nyquist GG, Moore N, Anand VK, Schwartz TH (2010) Endoscopic endonasal transclival resection of chordomas: operative technique, clinical outcome, and review of the literature. J Neurosurg 112:1061–1069CrossRefPubMed Fraser JF, Nyquist GG, Moore N, Anand VK, Schwartz TH (2010) Endoscopic endonasal transclival resection of chordomas: operative technique, clinical outcome, and review of the literature. J Neurosurg 112:1061–1069CrossRefPubMed
9.
go back to reference Hindi N, Casali PG, Morosi C, Messina A, Palassini E, Pilotti S, Tamborini E, Radaelli S, Gronchi A, Stacchiotti S (2015) Imatinib in advanced chordoma: a retrospective case series analysis. Eur J Cancer 51:2609–2614CrossRefPubMed Hindi N, Casali PG, Morosi C, Messina A, Palassini E, Pilotti S, Tamborini E, Radaelli S, Gronchi A, Stacchiotti S (2015) Imatinib in advanced chordoma: a retrospective case series analysis. Eur J Cancer 51:2609–2614CrossRefPubMed
10.
go back to reference Ito E, Saito K, Okada T, Nagatani T, Nagasaka T (2010) Long-term control of clival chordoma with initial aggressive surgical resection and gamma knife radiosurgery for recurrence. Acta Neurochir 152:57–67 discussion 67 CrossRefPubMed Ito E, Saito K, Okada T, Nagatani T, Nagasaka T (2010) Long-term control of clival chordoma with initial aggressive surgical resection and gamma knife radiosurgery for recurrence. Acta Neurochir 152:57–67 discussion 67 CrossRefPubMed
11.
go back to reference Jensen AD, Nikoghosyan A, Ellerbrock M, Ecker S, Debus J, Munter MW (2011) Re-irradiation with scanned charged particle beams in recurrent tumours of the head and neck: acute toxicity and feasibility. Radiother Oncol 101:383–387CrossRefPubMed Jensen AD, Nikoghosyan A, Ellerbrock M, Ecker S, Debus J, Munter MW (2011) Re-irradiation with scanned charged particle beams in recurrent tumours of the head and neck: acute toxicity and feasibility. Radiother Oncol 101:383–387CrossRefPubMed
12.
go back to reference Kaiser TE, Pritchard DJ, Unni KK (1984) Clinicopathologic study of sacrococcygeal chordoma. Cancer 53:2574–2578CrossRefPubMed Kaiser TE, Pritchard DJ, Unni KK (1984) Clinicopathologic study of sacrococcygeal chordoma. Cancer 53:2574–2578CrossRefPubMed
13.
go back to reference Lipplaa A, Dijkstra S, Gelderblom H (2016) Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series. Clin Sarcoma Res 6:19CrossRefPubMedPubMedCentral Lipplaa A, Dijkstra S, Gelderblom H (2016) Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series. Clin Sarcoma Res 6:19CrossRefPubMedPubMedCentral
14.
go back to reference McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM (2001) Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control 12:1–11CrossRefPubMed McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM (2001) Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control 12:1–11CrossRefPubMed
15.
go back to reference Migliorini DVR, Belkouch MC, Luy P, Blaser S (2015) First in man, phase 1 clinical trial combining encapsulation cell technology and irradiated autologous tumor cells for personalized cell-based immunotherapy. Safety, feasibility and clinical outcome results. Eur J Cancer 51:S114–S114CrossRef Migliorini DVR, Belkouch MC, Luy P, Blaser S (2015) First in man, phase 1 clinical trial combining encapsulation cell technology and irradiated autologous tumor cells for personalized cell-based immunotherapy. Safety, feasibility and clinical outcome results. Eur J Cancer 51:S114–S114CrossRef
16.
go back to reference Potluri S, Jefferies SJ, Jena R, Harris F, Burton KE, Prevost AT, Burnet NG (2011) Residual postoperative tumour volume predicts outcome after high-dose radiotherapy for chordoma and chondrosarcoma of the skull base and spine. Clin Oncol (R Coll Radiol) 23:199–208CrossRef Potluri S, Jefferies SJ, Jena R, Harris F, Burton KE, Prevost AT, Burnet NG (2011) Residual postoperative tumour volume predicts outcome after high-dose radiotherapy for chordoma and chondrosarcoma of the skull base and spine. Clin Oncol (R Coll Radiol) 23:199–208CrossRef
17.
go back to reference Samii A, Gerganov VM, Herold C, Hayashi N, Naka T, Mirzayan MJ, Ostertag H, Samii M (2007) Chordomas of the skull base: surgical management and outcome. J Neurosurg 107:319–324CrossRefPubMed Samii A, Gerganov VM, Herold C, Hayashi N, Naka T, Mirzayan MJ, Ostertag H, Samii M (2007) Chordomas of the skull base: surgical management and outcome. J Neurosurg 107:319–324CrossRefPubMed
18.
go back to reference Stacchiotti S, Longhi A, Ferraresi V, Grignani G, Comandone A, Stupp R, Bertuzzi A, Tamborini E, Pilotti S, Messina A, Spreafico C, Gronchi A, Amore P, Vinaccia V, Casali PG (2012) Phase II study of imatinib in advanced chordoma. J Clin Oncol 30:914–920CrossRefPubMed Stacchiotti S, Longhi A, Ferraresi V, Grignani G, Comandone A, Stupp R, Bertuzzi A, Tamborini E, Pilotti S, Messina A, Spreafico C, Gronchi A, Amore P, Vinaccia V, Casali PG (2012) Phase II study of imatinib in advanced chordoma. J Clin Oncol 30:914–920CrossRefPubMed
19.
go back to reference Stuer C, Schramm J, Schaller C (2006) Skull base chordomas: management and results. Neurol Med Chir (Tokyo) 46:118–124 discussion 124-115 CrossRef Stuer C, Schramm J, Schaller C (2006) Skull base chordomas: management and results. Neurol Med Chir (Tokyo) 46:118–124 discussion 124-115 CrossRef
20.
go back to reference Suit H, Kooy H, Trofimov A, Farr J, Munzenrider J, DeLaney T, Loeffler J, Clasie B, Safai S, Paganetti H (2008) Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No. Radiother Oncol 86:148–153CrossRefPubMed Suit H, Kooy H, Trofimov A, Farr J, Munzenrider J, DeLaney T, Loeffler J, Clasie B, Safai S, Paganetti H (2008) Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No. Radiother Oncol 86:148–153CrossRefPubMed
21.
go back to reference Tamaki M, Aoyagi M, Kuroiwa T, Yamamoto M, Kishimoto S, Ohno K (2007) Clinical course and autopsy findings of a patient with clival chordoma who underwent multiple surgeries and radiation during a 10-year period. Skull Base 17:331–340CrossRefPubMedPubMedCentral Tamaki M, Aoyagi M, Kuroiwa T, Yamamoto M, Kishimoto S, Ohno K (2007) Clinical course and autopsy findings of a patient with clival chordoma who underwent multiple surgeries and radiation during a 10-year period. Skull Base 17:331–340CrossRefPubMedPubMedCentral
22.
go back to reference Tzortzidis F, Elahi F, Wright D, Natarajan SK, Sekhar LN (2006) Patient outcome at long-term follow-up after aggressive microsurgical resection of cranial base chordomas. Neurosurgery 59:230–237 discussion 230-237 CrossRefPubMed Tzortzidis F, Elahi F, Wright D, Natarajan SK, Sekhar LN (2006) Patient outcome at long-term follow-up after aggressive microsurgical resection of cranial base chordomas. Neurosurgery 59:230–237 discussion 230-237 CrossRefPubMed
23.
go back to reference Walcott BP, Nahed BV, Mohyeldin A, Coumans JV, Kahle KT, Ferreira MJ (2012) Chordoma: current concepts, management, and future directions. Lancet Oncol 13:e69–e76CrossRefPubMed Walcott BP, Nahed BV, Mohyeldin A, Coumans JV, Kahle KT, Ferreira MJ (2012) Chordoma: current concepts, management, and future directions. Lancet Oncol 13:e69–e76CrossRefPubMed
Metadata
Title
Clival chordoma: a single-centre outcome analysis
Authors
Max Jägersberg
Amir El Rahal
Philipp Dammann
Doron Merkler
Damien Charles Weber
Karl Schaller
Publication date
01-10-2017
Publisher
Springer Vienna
Published in
Acta Neurochirurgica / Issue 10/2017
Print ISSN: 0001-6268
Electronic ISSN: 0942-0940
DOI
https://doi.org/10.1007/s00701-017-3163-7

Other articles of this Issue 10/2017

Acta Neurochirurgica 10/2017 Go to the issue